NCT07227909
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 5 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Stopped Trial status changed: Not Yet Recruiting → Suspended Sponsor's reason: PI Request
- Minor Enrollment target: 83 to 90
- Notable Eligibility criteria expanded, about 74 words
- Study description expanded, about 5 words
- Notable Start date: May 4, 2026 to Nov 4, 2026v4
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Two supervised oral doses 1 week apart prior to chemotherapy cycle 1 (Day 7 and Day 14), followed by two monthly supervised doses prior to chemotherapy cycles 2 and 3 (Day 42 and Day 70); total 4 doses.
Subperceptual dosing every other day for 2 weeks during the pre-chemotherapy run-in (mailed 7×1 mg capsules in tamperevident packaging) prior to the first three cycles as above (21 total doses)
Standard of Care: Chemotherapy and supportive care per institutional guidelines; no study drug.
Drugs: Psilocybin (drug)
Other: Standard of Care (SOC)
Sites
1 site in 1 country
- MD Anderson Cancer CenterHouston, Texas, United States